Key Takeaways
- • DropGenie, a Cambridge, MA-based functional biology company, raised $5M in Seed+ funding, according to FinSMEs.
- • Backers include BDC Thrive Venture Fund, Skeleton Key, Merck Global Health Innovation Fund, CQDM, Real Ventures, and Anges Quebec.
- • Proceeds will accelerate commercialization of the company's first product and expand customer engagement models, including lab-run protocols, studies as a service, and strategic data partnerships.
- • DropGenie's automated microfluidic platform miniaturizes gene editing workflows directly in primary patient cells, targeting cell therapy, functional genomics, and AI-driven drug development.
Summary
DropGenie, a Cambridge, Massachusetts-based functional biology company, has raised $5M in Seed+ funding, according to FinSMEs. The company generates decision-ready discovery data from patient-derived cells. Its CEO is Alison Hirukawa.
The round drew a mix of venture, strategic, and public-linked investors. Backers include BDC Thrive Venture Fund, Skeleton Key, Merck Global Health Innovation Fund, CQDM, Real Ventures, and Anges Quebec.
DropGenie plans to use the proceeds to accelerate commercialization of its first product. The company also intends to expand its customer engagement models, which include lab-run protocols, studies as a service, and strategic data partnerships, and to grow its global footprint.
The company's technology is an automated microfluidic platform that miniaturizes gene editing workflows directly in primary patient cells. According to the company's description, this allows drug developers to scale experiments using scarce primary human cells. The platform supports cell therapy, functional genomics, and AI-driven drug development.
The source article does not disclose a valuation, revenue figures, or the lead investor in the round.
The round drew a mix of venture, strategic, and public-linked investors. Backers include BDC Thrive Venture Fund, Skeleton Key, Merck Global Health Innovation Fund, CQDM, Real Ventures, and Anges Quebec.
DropGenie plans to use the proceeds to accelerate commercialization of its first product. The company also intends to expand its customer engagement models, which include lab-run protocols, studies as a service, and strategic data partnerships, and to grow its global footprint.
The company's technology is an automated microfluidic platform that miniaturizes gene editing workflows directly in primary patient cells. According to the company's description, this allows drug developers to scale experiments using scarce primary human cells. The platform supports cell therapy, functional genomics, and AI-driven drug development.
The source article does not disclose a valuation, revenue figures, or the lead investor in the round.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.